Correspondingly, the United States Food and Drug Administration (FDA) approved dapagliflozin as the first SGLT2 inhibitors to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with or without T2DM in 2020 (U. S. Food and Drug Administration, 2020). This evidence concerns the gene SLC5A2 and heart failure.